Scientists Startled by Discovery of Small Star Swimming Through Outer Layers of Another Larger Star
The findings, detailed in a new study published in the journal Science, are an incredibly rare example of a "spider star" that preys on its companion, so-named because of the female arachnids that devour males after mating. And tantalizingly, the grisly scene is some of the best evidence yet of a stage of stellar evolution called the common envelope phase, which has never been directly observed by astronomers.
Pulsars are rapidly spinning neutron stars, the incredibly dense stellar cores that are left over in the aftermath of a supernova.
Everything about neutron stars exhaust superlatives — their gravity most of all. They are so tightly packed, containing more mass than our Sun inside a form just a dozen miles in radius, that all their atoms and their constituent protons and electrons have been crushed into neutrons, with just a teaspoon of this improbable matter weighing trillions of pounds. Their powerful magnetic fields, billions of times stronger than Earth's, unleash beams of radio waves into space along their poles.
Further beggaring belief, some neutron stars become pulsars, which spin up to hundreds of times per second after siphoning material from a stellar companion, if it has one. Their sweeping beams of radiation, like cosmic lighthouses, look like a repeating signal to observers.
The newly discovered pulsar, PSR J1928+1815, intrigued the astronomers because its radio pulses suggested that it was extremely close to its host, completing an orbit every 3.6 hours. They also noticed that for one-sixth of that orbit, the pulsar would vanish from view, indicating that the host was eclipsing it.
"That's a large part of the orbit," coauthor Jin-Lin Han, a radio astronomer at the National Astronomical Observatories in Beijing, told Gizmodo. "That's strange, only a larger companion can do this."
Over four and a half years, Han's team closely observed the system using the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) in southern China, the largest and most powerful single-dish radio telescope in the world.
Their observations revealed that the host star was between one to 1.6 times the mass of our Sun, while the pulsar was more likely 1.4 stellar masses. Determining the make of the host star, however, took some additional sleuthing. Its tight orbit and the fact that it was only detectable in radio wavelengths, Giz noted, ruled out its being a Sun-like star. And since it was large enough to eclipse the pulsar, it had to be something larger than a stellar remnant like another neutron star.
That pointed to something altogether more spectacular: a helium star, created after the pulsar, when it was still an ordinary neutron star, tore off its host's layers and created a huge common envelope, a cloud of hydrogen gas that swallows both the stars. In this case, the poor star under attack managed to cling on to its evacuated innards for just 1,000 years — a blink in a stellar lifespan — before the whole, mighty envelope fell apart. Fleeting as it was, its impact is lasting: the friction exerted by the gases gradually nudged both stars closer together.
Common envelopes are rare because the process of a neutron star stripping its companion, which causes it to spin and graduate to a pulsar, usually results in all the siphoned material being devoured. But if the companion is massive enough, much of it survives.
The discovery marks the first spider star found orbiting a helium star. While the astronomers didn't get to witness the envelope in action, this is some of the most convincing evidence to date that this long-theorized stage of stellar evolution exists. In all, the team estimates that there're just 16 to 84 star systems like this one in the entire Milky Way — and, against all odds, we got to see one.
More on space: Scientists Puzzled by Mysterious Motion in Atmosphere of Saturn's Moon
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
A Fragment of Earth's Original Crust Still Exists—and It's Buried in Canada
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn in this story: What are now thought to be the oldest rocks on Earth have been confirmed to have an age of almost 4.2 billion years, almost as old as the planet itself. Researchers were met with controversy for their initial claims, but dating isotopes of one metal that decayed into another showed that the igneous rock from northeastern Canada really was that old. This ancient piece of our planet could tell us more about its turbulent past. Earth is about 4.5 billion years old, and as the eons passed, the crust of the young planet experienced turbulence. Asteroid collisions shattered some parts, which melted and recrystallized, while tectonic plates constantly shifted and triggered volcanic eruptions that oozed magma over the surface. Erosion further erased evidence of our planet's early scars. The most ancient layers of crust were all but lost—until now. The oldest crust on our planet formed during what is known as the Hadean epoch. Reaching back to the period between 4.6 to 4 billion ago, this was when the Solar System was still forming in a thick haze of gas and dust (possibly the refuse from a supernova) that surrounded the nascent Sun. It is an epoch not even considered part of geologic time because, for years, the only rocks found dating back from this period were meteorites that fell from space. Hadean meteorites and lunar rocks up to 4.5 billion years old have been found before, but nothing directly from Earth even came close. As Earth became covered in swaths of ocean, layers of soil and landscapes as diverse as forests, deserts, mountains, volcanic plains, glaciers, grasslands and cities built by humans, primordial relics were buried even deeper. Anything found to have been part of our planet's crust in the distant past was 3.8 billion years old or younger. That puts even our latest findings in the Archean period, which followed the Hadean. Geologist Jonathan O'Neil of Ottawa University in Canada refused to believe there were no Hadean fragments of crust remaining. While zircons found embedded in Australian rocks were successfully dated back to that period, an actual piece of crust that old had never surfaced. In a controversial 2008 study, O'Neil and his research team claimed that they had discovered a part of the original crust in northeast Canada's remote Nuvvuagittuq Greenstone Belt. This formation has stayed intact almost since Earth was born. It could be a portal into Earth's earliest growing pains. There was just one problem. Another group of researchers steadfastly argued that the rocks of the Nuvvuagittuq Greenstone Belt were no older than 3.8 billion years. While the 4-billion-year-old rocks of the Acasta gneiss in the northwest of Canada were slightly older, having just barely formed at the end of the Hadean, they were still not old enough. O'Neil was determined to prove that the Nuvvuagittuq rock, originally a flood plain of magma that hardened into volcanic basalt, predated the other pieces of crust. It turned out that the evidence was hiding in the rock itself, and not in the form of zircons. When they first formed, they had contained samarium, a metal which oxidizes when exposed to air. Any samarium in the rocks was long gone. However, samarium isotopes had left behind chemical signatures of their decay into isotopes of neodymium. Two different isotopes of neodymium which had come from two samarium isotopes were both dated to 4.16 billion years. 'The age agreement between both extant and extinct radiogenic systems, in rocks related through igneous fractionation, is compelling evidence for preservation of Hadean rocks in the Nuvvuagittuq Greenstone Belt, opening a rare window into Earth's earliest times,' O'Neil and his colleagues said in a study recently published in Science. There could be more crust that ancient which has not been unearthed yet. It is even possible that some may have landed on the Moon. 4.4 billion years ago, not long after Earth formed, an extreme collision shattered part of the Earth and formed our only satellite, which has not been explored by humans since the Apollo Era. What future Artemis astronauts find once we return to the Moon might give us more insight about how our planet grew up. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Yahoo
an hour ago
- Yahoo
125,000-year-old 'fat factory' run by Neanderthals discovered in Germany
When you buy through links on our articles, Future and its syndication partners may earn a commission. Neanderthals were running a potentially lifesaving "fat factory" around 125,000 years ago in what is now Germany, a new study finds. The research, published Wednesday (July 2) in the journal Science, reveals that these archaic human relatives had a process for extracting grease from animal bones — and it may have saved them from a lethal condition. The condition, known as protein poisoning or rabbit starvation, happens when humans eat too much protein and don't get enough fat or carbohydrates. Neanderthals would have likely been at high risk of protein poisoning, as they largely ate meat. The "fat factory" discovery suggests that hominins, or humans and our close relatives, were practicing resource intensification — getting more utility out of the materials they had available — much earlier than previously thought. Before this analysis, the earliest evidence for resource intensification dated to 28,000 years ago, long after the Neanderthals' extinction, according to the study. Scientists found the Paleolithic factory after uncovering the fragmented remains of 172 large animals, including horses, deer and cattle, as well as Neanderthal-made anvils and hammerstones. After analyzing the bones, the team found that Neanderthals had first smashed the bones to get to the marrow — a soft, edible tissue inside of some bones — before boiling them to extract the fat. It appears that Neanderthals ate both the marrow and the fat, which would have maximized the amount of food and nutrients they got from an animal carcass. "It's surprisingly creative and innovative behavior from Neanderthals," Osbjorn Pearson, an archaeologist at The University of New Mexico who was not involved in the study, told Live Science. Related: 10 fascinating discoveries about Neanderthals in 2024, from 'Thorin' the last Neanderthal to an ancient glue factory Neanderthals, the closest extinct relative of modern humans, emerged around 400,000 years ago and went extinct around 34,000 years ago. Remains of the archaic humans were first discovered in the 19th century, and much of the archaeological evidence revealed since then suggests that Neanderthals were fairly sophisticated. They made tools, glue factories and possibly even art. While it was known that Neanderthals largely ate meat, little was known about how Neanderthals prepared animal carcasses. "We know a lot about Neanderthal hunting tactics, habits and consumption of meat and bone marrow … but to much lesser degree about all the processes after hunting and butchering," study first author Lutz Kindler, an archaeologist at the Monrepos Archaeological Research Center and Museum for Human Behavioral Evolution in Germany, told Live Science in an email. Archaeologists found 2,000 bone fragments at Neumark-Nord, an archaeological site in central Germany, that had been crushed to facilitate the grease extraction. "Fragmentation of the bones of large mammals into such a vast amount of small fragments is labour-intensive and time-consuming," so it's clear they served a purpose, study co-author Wil Roebroeks, a professor emeritus of paleolithic archaeology at Leiden University in the Netherlands, told Live Science in an email. In addition to bearing signs of being boiled, the bones are mostly broken near areas that contain the most fat, which supports the idea that the grease was rendered for consumption. Neanderthals might have eaten the fat out of necessity, Pearson said. They sometimes experienced periods of starvation and may have been desperate for sources of calories. "And it turns out that fat is just packed with calories," he said — fat supplies more than twice the calories per gram as carbohydrates and protein do. The bones also suggest that these archaic humans may have used some form of food storage, Roebroeks said. Neanderthals may have been "more similar to historically documented foragers" than previous research had suggested, he added. RELATED STORIES —130,000-year-old Neanderthal-carved bear bone is symbolic art, study argues —50,000-year-old Neanderthal bones harbor oldest-known human viruses —Neanderthal 'population bottleneck' around 110,000 years ago may have contributed to their extinction Kindler noted the overlaps between the revealed Neanderthal practice and modern human behavior. "The archaeological science of studying hominids is about finding the similarities between us today and them in the past," he said. Understanding what Neanderthals ate and how they acquired it may improve our understanding of human adaptations, Roebroeks said. The extra calories provided by bone-derived grease has been vital to human evolution, as more robust diets can lengthen lifespan and lead to increased reproduction.
Miami Herald
3 hours ago
- Miami Herald
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
